Search research articles
Contact Us
Filters
Showing results (151-160 of 253) with videos related to
Page
of 26
Sort By:
Cancer Causes & Control : CCC
|
April 4, 2008
Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma
Brian C-H Chiu, Bhavana J Dave, Mary H Ward, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 15, 2019
Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma
Nitika Paudel, Derek Schulze, Ryan D Gentzler, et al.
Bone Marrow Transplantation
|
January 31, 2006
Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation
S Singhal, L I Gordon, M S Tallman, et al.
American Journal of Clinical Pathology
|
July 17, 2008
CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease
Katalin Kelemen, Loann C Peterson, Irene Helenowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP
Andrew M Evens, Laurie H Sehn, Pedro Farinha, et al.
Blood Cancer Journal
|
May 12, 2025
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403
Craig A Portell, Opeyemi A Jegede, Nina Wagner-Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2015
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
Andrew M Evens, Sriram Balasubramanian, Julie M Vose, et al.
Blood
|
November 26, 2011
A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era
Andrew M Evens, Irene Helenowski, Erika Ramsdale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2018
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma
Andrew M Evens, Ranjana H Advani, Irene B Helenowski, et al.
Cancer
|
February 18, 2021
SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center
Mansi R Shah, Imraan Jan, Jeremy Johns, et al.
Page
of 26
Search research articles
Search
Showing results (151-160 of 253) with videos related to
Sort By:
Page
of 26
Cancer Causes & Control : CCC
|
April 4, 2008
Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma
Brian C-H Chiu, Bhavana J Dave, Mary H Ward, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 15, 2019
Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma
Nitika Paudel, Derek Schulze, Ryan D Gentzler, et al.
Bone Marrow Transplantation
|
January 31, 2006
Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation
S Singhal, L I Gordon, M S Tallman, et al.
American Journal of Clinical Pathology
|
July 17, 2008
CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease
Katalin Kelemen, Loann C Peterson, Irene Helenowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP
Andrew M Evens, Laurie H Sehn, Pedro Farinha, et al.
Blood Cancer Journal
|
May 12, 2025
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403
Craig A Portell, Opeyemi A Jegede, Nina Wagner-Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2015
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
Andrew M Evens, Sriram Balasubramanian, Julie M Vose, et al.
Blood
|
November 26, 2011
A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era
Andrew M Evens, Irene Helenowski, Erika Ramsdale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2018
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma
Andrew M Evens, Ranjana H Advani, Irene B Helenowski, et al.
Cancer
|
February 18, 2021
SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center
Mansi R Shah, Imraan Jan, Jeremy Johns, et al.
Page
of 26